Wednesday, September 16, 2026Latest filing Sep 14, 2026

SBFM Congressional Stock Trades

Sunshine Biopharma Inc. - Common stock (SBFM)

Last disclosed trade Jun 30

Every disclosed trade in SBFM by members of Congress under the STOCK Act, parsed by Coldpine. Informational only, sourced from public filings. Not investment advice.

Sample · the intelligence layer

Coldpine signal scoreA 0-1 composite from four weighted factors: disclosure speed, trade size, cluster activity (multiple members buying the same name), and the member’s track record. ≥ 0.65 is the high-conviction tier; ≥ 0.50 is moderate. Trades from trust-managed members are penalized (× 0.2 multiplier). It’s research, not a recommendation.

Roger Williams · Bought $SBFM · Jun 30 · $1K–$15K

0.21LOW
Disclosure speedx 0.250.10
Trade sizex 0.250.20
Cluster activityx 0.150.00
Track recordx 0.350.39

Every disclosed trade in the database gets this treatment: a four-factor score and a written read from Coldpine’s AI-based analysis. Informational only, not investment advice. Create a free account for every scored trade →

Follow $SBFM

Get notified when any member of Congress trades $SBFM. Free, no card, no spam.

Follow free →
1
Disclosed trades
1
Buys
0
Sells
1
Members trading

The record on $SBFM

Coldpine has parsed 1 disclosed trade in $SBFM by 1 member of Congress, drawn from 1 periodic transaction report dated Jun 30, 2022. It came from the House, filed by a Republican.

The one trade with a known filing lag was reported 713 days after the trade date, outside the 45-day window the STOCK Act sets: a $SBFM purchase by Roger Williams dated Jun 30, 2022, disclosed Jun 12, 2024. How late filing is measured across all of Congress is in the late-filers study.

The one trade that lists an account holder was reported under a spouse, dependent child, or joint account rather than the member directly.

Members who trade SBFM

Recent disclosed trades in SBFM

DateMemberTypeAmount
Jun 30Roger Williams(TX)buy$1K–$15K

Data sourced from public STOCK Act disclosures. Coldpine is a publisher of intelligence on congressional disclosures, not an investment adviser. See full history and scores, free with an account →